TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy of Pediatric Lipid Screening Alerts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* male or female patients between the ages of 9 - 11~* seen within a primary care, cardiology, endocrinology, urgent care (CareWorks), or nutrition clinic at Geisinger~Exclusion criteria:~* patients who have completed a lipid screen in the EMR~* patients who were determined to have familial hypercholesterolemia based on prior screening

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Passive Control (Type: NO_INTERVENTION): Will consist of no alerts and will serve to examine lipid panel screening rates given the current standard of care. After 6 months, providers in this (and other conditions) will receive the alert(s) with the best demonstrated success in increasing screening rates.
- Best Practice Alert (BPA-only) (Type: EXPERIMENTAL): Will consist of a BPA that fires for providers during a visit with an eligible 9-11 year-old patient. This is an active opt-in alert wherein the provider must respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test. The BPA will include a recommendation to administer the screen in combination with existing scheduled bloodwork.
- Health Maintenance Topic (HMT-only) (Type: EXPERIMENTAL): Will consist of an HMT in Epic that is present for providers at their visit with an eligible patient. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
- BPA+HMT (Type: EXPERIMENTAL): Will consist of both the BPA and HMT presented simultaneously in Epic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening~2. Active UC confirmed by endoscopy~Exclusion criteria:~1. Severe extensive colitis~2. Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD~3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etrasimod 2 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EASSI - Evaluation of the Safety of Self-Administration With Icatibant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet the following criteria to be enrolled in this study.~1. Males and females 18 years of age at the time of informed consent~2. Documented diagnosis of HAE Type I or II based on ALL of the following criteria:~   * Family and/or medical history~  * Characteristic attack manifestations, recurrent attacks~  * Historical functional C1-INH \<50% normal values~3. Women of childbearing potential must use consistently and correctly a highly effective, adequate method of birth control (failure rate less than 1% per year) - sexual abstinence or have a vasectomised partner during the duration of the study. Hormonal contraception can be continued if verified by a physician that it doesn't affect the course of HAE attacks.~4. Mental and physical condition allowing patients to complete baseline assessment, to self-administer icatibant and to follow other study procedures.~5. Ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient.~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded from the study.~1. Participation in a clinical trial of another investigational medicinal product within the past month (except a previous icatibant study).~2. Diagnosis of angioedema other than Type I or Type II HAE.~3. Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.~4. Congestive heart failure (NYHA Class 3 and 4).~5. Stroke within the past 6 months.~6. Treatment with angiotensin converting enzyme (ACE) inhibitor.~7. Pregnancy and/or breast-feeding.~8. In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.~9. In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.~10. In the opinion of the investigator: inability to manage study medication or self-administration of an injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Icatibant- Naive Treatment Phase (Type: EXPERIMENTAL): Single subcutaneous injection of icatibant, 30 mg
- icatibant- Self administration Phase (Type: EXPERIMENTAL): Single subcutaneous injection of icatibant, 30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Catheter With or Without Adductor Canal Nerve Block for Postoperative Analgesia Following Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* end stage degenerative joint disease~* enrolled for unilateral total knee arthroplasty at the University of Chicago~* age \< 85~* ability to understand and willingness to sign a written informed consent~Exclusion Criteria:~* age \> 85~* American Society of Anesthesiologists physical status \> 3~* known hypersensitivity to lidocaine, bupivacaine, ropivacaine or other local anesthetic agents~* Coagulopathy, specifically INR \> 1.5, Platelets \< 100, therapy with clopidogrel within 5 days prior to surgery, enoxaparin or fondaparinux within the last 24 hours prior to surgery, patients with anti-phospholipid syndrome requiring aggressive anticoagulation perioperatively~* History of alcohol or substance abuse (including strong opioids - morphine, oxycodone, methadone, fentanyl, ketobemidone), taking \> 50 mg morphine equivalent daily of opioids~* Pre-existing femoral neuropathy or radiculopathy~* Patients with poor ability to communicate

- Gender: ALL
- Minimum Age: None
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Epidural Catheter without Adductor Canal Nerve Block Catheter (Type: SHAM_COMPARATOR): Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
- Epidural Catheter with Adductor Canal Nerve Block Catheter (Type: EXPERIMENTAL): Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women with T scores less than -2.5 (groups A and C)~* The periodontitis patients were selected based on the radiographical evidence of bone loss, presence of four or more sites with bleeding on probing (BOP), ≥5 mm pocket depth (PD) and ≥6 mm clinical attachment loss (CAL).~* The clinically healthy control groups were selected on the basis of no radiographic bone loss or CAL and PD≤3 mm.~Exclusion Criteria:~* Any known systemic disease rather than osteoporosis~* Smoking~* Antibiotic therapy within the last 3 months~* Periodontal treatment in the last 6 months

- Gender: FEMALE
- Minimum Age: 51 Years
- Maximum Age: 66 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): * Subjects with chronic periodontitis and osteoporosis.~* Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.
- Group B (Type: ACTIVE_COMPARATOR): * Subjects with chronic periodontitis and systemically healthy.~* Phase 1 periodontal theraphy was administered to the subjects.
- Group C (Type: ACTIVE_COMPARATOR): * Subjects with periodontally healthy and osteoporosis.~* Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.
- Group D (Type: NO_INTERVENTION): * Systemically and periodontally healthy controls~* No intervention has been made.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have locally advanced/borderline resectable hepatocellular carcinoma.~2. Must have measurable disease.~3. Age ≥18 years.~4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~5. Patients must have adequate organ and marrow function defined by study-specified laboratory tests.~6. Patients must have adequate liver remnant and function.~7. Antiviral therapy per local standard of care for hepatitis B.~8. Woman of child bearing potential must have a negative pregnancy test.~9. Must use acceptable form of birth control while on study.~10. Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~1. Fibrolamellar carcinoma or mixed HCC.~2. Chemotherapy, radiotherapy, investigational therapy, or surgery less than 6 months prior to trial registration.~3. Concomitant Anticoagulation therapy.~4. Any GI or pulmonary risks of bleeding.~5. History of HIV Infection.~6. Active co-infection with hepatitis B and hepatitis C.~7. Active co-infection with hepatitis B and hepatitis D.~8. Has a diagnosis of immunodeficiency, or is receiving systemic steroid therapy.~9. History of any autoimmune disease requiring systemic treatment within the past 2 years. Any patient bearing an allograft is not eligible.~10. Any additional malignancies with treatment or life-limiting cancers. Superficial bladder cancer, non-melanoma skin cancers, or low grade prostate cancer not requiring therapy would not exclude participation in this trial.~11. Uncontrolled intercurrent illness.~12. Corrected QT interval calculated by the Fridericia formula.~13. Uncontrolled high blood pressure.~14. Are pregnant or breastfeeding.~15. Any gastrointestinal (GI) disorders.~16. Any certain study-specified heart conditions 6 months prior to enrollment.~17. Major surgery within 2 months before enrollment.~18. Have any evidence of moderate or severe ascites.~19. Any untreated or incompletely treated varices with bleeding or high-risk bleeding.~20. Inability to swallow intact tablets.~21. Known or suspected hypersensitivity to study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic heart failure patients in dilated stages~* Etiologies: dilated cardiomyopathy, chronic hypertensive cardiopathy in dilated stage, chronic coronary cardiopathy in dilated stage~* Ejection fraction ≤ 40%.~* Patients who are stable under optimal medical treatment for a period of at least 3 months prior to randomization~Exclusion Criteria:~* Severe or persistent heart failure~* Recurrent myocardial ischemia~* Uncontrolled ventricular tachycardia~* Malignant disease (life expectancy of less than one year)~* Manifest ventricular asynchrony~* Hematologic disease~* Recent cerebrovascular disease~* Recent acute coronary syndrome~* Serum creatinine \>2.26 mg/dL (200 umol/L)~* Atrial fibrillation without heart rate control in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ucMSC (Type: EXPERIMENTAL): Umbilical cord derived mesenchymal are injected intravenously to Patients.
- Controls (Type: PLACEBO_COMPARATOR): Intravenous placebo solution are administrated to Patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Welchol as Monotherapy for Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects \>= 18 years of age;~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception as detailed in the protocol.~* Diagnosis of Type 2 Diabetes Mellitus;~* HbA1C \>= 7.5% and =\< 9.5 % at screening;~* Fasting C-peptide \>0.5 ng/mL at screening;~* Drug naïve (no prior treatment with OAD) or having received no pharmacologic therapy for diabetes for the 3 month period prior to screening;~* Clinically stable in regards to medical conditions other than type 2 diabetes;~* Concomitant medications must be at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period; and~* Fasting glucose =\< 240 mg/dL at randomization~Exclusion Criteria:~* A history of type 1 diabetes and/or a history of ketoacidosis;~* History of bowel obstruction;~* History of hypertriglyceridemia-induced pancreatitis;~* Fasting serum triglyceride concentrations \>500 mg/dL;~* History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal (GI) motility disorders, or major GI surgery;~* History of insulin use of \>= 2 weeks duration in the previous 3 months or a total of \> 2 months of insulin therapy at any time prior to screening;~* Two or more fasting self-monitored blood glucose (SMBG) levels \>240 mg/dL during the placebo lead-in period.~* Previous treatment with a bile acid sequestrant, including Welchol within the 3 months prior to screening;~* Body mass index (BMI) \>40 kg/m2;~* Weight loss \> 3% in prior 3 months; and~* LDL \<60 mg/dL.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Welchol (Type: EXPERIMENTAL): Welchol 625mg tablets
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* Patients who received DEXTENZA insertion perioperatively.~Exclusion Criteria:~* Any patient who did not receive DEXTENZA insertion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dextenza recepient (Type: None): A Retrospective Review DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults at least 18 years of age~2. Current smoker (\>5 cigarettes per day for the past 3 months)~3. Able to speak and read English or Spanish~4. Agree to participate in the study and be available for 6 weeks of treatment and 6 months of follow-up~5. Willing to set a quit date within 2 weeks of enrollment date~6. Identify as being of Latino heritage, ethnicity, or ancestry~Exclusion Criteria:~1. Individuals suffering from any unstable medical condition precluding the use of NRT (Identified using the Medical History Questionnaire given at baseline)~2. Currently using smokeless tobacco, electronic nicotine delivery systems (ENDS), nicotine replacement therapy, or other smoking cessation treatment~3. Pregnant or nursing~4. Suffering from a severe psychiatric disorder (assessed using self-reporting history of psychiatric diagnosis during the phone screening) that would interfere with participation~5. Diagnosis of substance dependence other than nicotine (screened using DSM IV TR criteria) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition~6. Individuals that do not have access to a working telephone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Health Education (HE) Group (Type: EXPERIMENTAL): Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
- Culturally Tailored Smoking Cessation (CTSC) Group (Type: EXPERIMENTAL): Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
- Culturally Tailored Smoking + Adherence Enhancement (AE) Group (Type: EXPERIMENTAL): Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-45 years inclusive at the time of consent. The date of signing informed consent is defined as the beginning of the screening period. This inclusion criteria will only be assessed at the screening visit.~* Subject is willing to comply with any applicable contraceptive requirements of the protocol and is: male, or non-pregnant non lactating female, or females must be at least 90 days post-partum or nulliparous.~* Satisfactory medical assessment with no clinically or relevant abnormalities in medical history, physical examination, vital signs, ECG, and clinical laboratory evaluation as assessed by the investigator.~Exclusion Criteria:~* Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or could affect clinical or laboratory assessments.~  a- Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.~* Significant illness, as judged by the Investigator, within 2 weeks of the first dose of investigational product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Anagrelide Therapeutic (0.5 mg) (Type: EXPERIMENTAL): None
- Anagrelide Supratherapeutic (2.5 mg) (Type: EXPERIMENTAL): None
- Moxifloxacin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete